16.01.2025 | Tracker
Top 50 Pharma Tracker: HCPs celebrate a successful quarter for oncology and obesity treatments
The Top 50 Pharmaceutical Companies mentioned by HCPs on X
Current Quarter Rank | Previous Quarter Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
---|---|---|---|---|---|
1 | 1 | Pfizer | 8,882 | 641 | 9 |
2 | 2 | Moderna | 3,867 | 236 | 9 |
3 | 4 | Johnson & Johnson | 1,877 | 346 | 4 |
4 | 6 | AstraZeneca | 1,289 | 517 | 46 |
5 | 3 | Novavax | 1,206 | 191 | 12 |
6 | 5 | GSK | 1,160 | 297 | 52 |
7 | 7 | Novo Nordisk | 1,093 | 601 | 41 |
8 | 14 | Lilly | 1,037 | 676 | 1 |
9 | 12 | Sanofi | 837 | 224 | 48 |
10 | 8 | Roche | 682 | 308 | 54 |
11 | 10 | Gilead Sciences | 564 | 230 | 10 |
12 | 11 | Merck & Co | 504 | 156 | 23 |
13 | 13 | Abbott | 475 | 452 | 28 |
14 | 16 | AbbVie | 472 | 341 | 68 |
15 | 9 | Bayer | 452 | 139 | 8 |
16 | 17 | Novartis | 405 | 213 | 16 |
17 | 20 | Amgen | 324 | 235 | 11 |
18 | 15 | Boehringer Ingelheim | 218 | 182 | 3 |
19 | 24 | Takeda | 205 | 194 | 0 |
20 | 28 | Daiichi Sankyo | 200 | 85 | 30 |
21 | 18 | Otsuka | 179 | 10 | 0 |
22 | 33 | Teva | 149 | 110 | 2 |
23 | 19 | BMS | 145 | 95 | 3 |
24 | 26 | Organon | 139 | 8 | 0 |
25 | 21 | Fresenius | 120 | 56 | 12 |
26 | 23 | Chugai | 110 | 5 | 5 |
27 | 22 | Regeneron | 81 | 41 | 3 |
28 | 25 | Astellas | 73 | 46 | 1 |
29 | 31 | STADA Arneimittel | 70 | 4 | 0 |
30 | 28 | UCB | 66 | 56 | 22 |
31 | 36 | Servier | 65 | 55 | 29 |
32 | 33 | Merck KGaA | 61 | 56 | 13 |
33 | 37 | Ipsen | 58 | 41 | 0 |
34 | 40 | Viatris | 52 | 3 | 0 |
35 | 30 | Biogen | 45 | 23 | 0 |
36 | 32 | Vertex | 44 | 44 | 1 |
37 | 42 | Menarini | 32 | 26 | 5 |
37 | 44 | Jazz Pharmaceuticals | 32 | 19 | 1 |
39 | 33 | Eisai | 31 | 19 | 4 |
40 | 26 | Dr. Reddy's Labratories | 30 | 7 | 0 |
41 | 45 | Grifols | 27 | 2 | 0 |
42 | 39 | CSL | 26 | 23 | 0 |
42 | 40 | Bausch | 26 | 9 | 1 |
44 | 43 | Incyte | 18 | 16 | 0 |
45 | 38 | Sun | 6 | 2 | 1 |
46 | 50 | Shanghai | 3 | 0 | 0 |
50 | 46 | Jiangsu Hengrui | 0 | 0 | 0 |
50 | 50 | Sino | 0 | 0 | 0 |
50 | 50 | Yunnan Baiyao Group | 0 | 0 | 0 |
50 | 50 | Mitsubishi Chemical Group | 0 | 0 | 0 |
2024 Q4’s insights from HCPs mentioning the Top 50 Pharmaceutical Companies
The five most mentioned pharmaceutical companies by HCPs on X between October and December 2024 were Pfizer, Moderna, Johnson & Johnson, AstraZeneca and Novavax.
CREATION.co identified 23,806 HCP mentions of pharmaceutical companies between October and December 2024, an increase of 9.43% compared to the previous quarter.
Oncology developments
On 08 October, Surgeon Bryan Bell shared a press release from Merck regarding the KEYNOTE-689 trial, which evaluated pembrolizumab for the treatment of locally advanced head and neck squamous cell carcinoma. According to the surgeon, this is “a disease that has not seen meaningful change in treatment in 40 years”. He finishes the post by congratulating Merck for the trial results, expressing his excitement for a potential new treatment paradigm.
YES! KN689 met primary endpoint! Finally, we may have a new (neoadjuvant) treatment paradigm for locally advanced HPV- HNSCC, a disease that has not seen meaningful change in treatment (or survival) in 40 years.Congrats @DrUppaluri @Merck et al https://t.co/sa93L41YBC
— R. Bryan Bell, MD, DDS, FACS, FRCS(Ed) (@rbryanbell) October 8, 2024
The news of the successful clinical trial resonated with his HCP peers, with 6 of them sharing his post.
In the world of prostate cancer, other exciting news for clinical trials has emerged. On 25 November, genitourinary (GU) oncologist María Natalia Gandur Quiroga wrote a post highlighting AstraZeneca’s CAPItello-281 trial. The post highlighted a few of the important developments, including a consistent safety profile with other medications, significant improvements in radiographic progression-free survival, and a step forward in addressing patient needs. She calls the results of the trial “exciting news in prostate cancer!”
💫🌟📢 Exciting news in prostate cancer! Key highlights from the CAPItello-281 trial on Truqap (#capivasertib)🌟💫@OncoAlert @AstraZeneca
🔹 First AKT inhibitor combination to show benefits in PTEN-deficient #mHSPC.
🔹 Significant improvement in rPFS vs. abiraterone + ADT with… pic.twitter.com/mVhuuALA9u— Dra. María Natalia Gandur Quiroga (@nataliagandur) November 25, 2024
The news of the clinical trial also caught the attention of GU Digital Opinion Leader (DOL) Toni Choueiri, tagging AstraZeneca in his post and sharing the press release.
First AKT inhibitor combination in hormone-sensitive PTEN-deficient prostate cancer: PFS benefit in CAPItello-281 Phase III trial
@AstraZeneca https://t.co/iiuNe2o0vM
— Toni Choueiri, MD (@DrChoueiri) November 25, 2024
The positive news of AstraZeneca’s trial was well received, with almost 40 HCPs online sharing the news.
On 30 November, breast cancer DOL Paolo Tarantino shared a post ahead of the San Antonio Breast Cancer Symposium (SABCS) 2024 where he stated his excitement for presenting research of four studies. He thanked his partners and colleagues for their collaboration, including Novartis, calling them “brilliant”.
10 days to #SABCS24. Excited to present at the conference the results of 4 studies, made possible by collaborations with brilliant @DanaFarber colleagues & with multiple external partners (@RevealGenomics, @Yale, @Novartis). Come meet me at the posters on December 11th and 12th! pic.twitter.com/LXJPnWptY2
— Paolo Tarantino (@PTarantinoMD) November 30, 2024
Obesity and weight loss developments
On 25 October, Type 2 Diabetes DOL Daniel Drucker shared a post about the weight loss space, calling the ongoing competition between competitors “a strong start”. He highlighted the innovation that has happened which has allowed more patients to get access to these treatments. He tagged many pharmaceutical companies including Novo Nordisk, Eli Lilly, Amgen, Roche and Pfizer.
After a strong start, competition for @novonordisk @EliLillyandCo is coming in the #weightloss space, with widespread innovation to bring options for more people @amgen @Roche @AltimmuneInc @StructureTx @Viking_VKTX @pfizer @Boehringer https://t.co/XAD2qoRPvX @TheEconomist pic.twitter.com/StJucWpemX
— Daniel J Drucker (@DanielJDrucker) October 25, 2024
On 01 November, Type 2 Diabetes DOL Cristobal Morales shared a press release from Novo Nordisk regarding the ESSENCE trial, evaluating semaglutide’s efficacy in treating liver fibrosis and metabolic dysfunction-associated steatohepatitis (MASH). He quotes the press release, highlighting the “superior improvement” that semaglutide had in both diseases.
https://t.co/089W97jcdv Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial @NovoNordiskES pic.twitter.com/gO4Bc815u3
— Cristobal Morales (@CristobMorales) November 1, 2024
Shared by 18 HCPs
The second most shared post discussing the ESSENCE trial when discussing a pharmaceutical company was from physician Manuel Romero-Gómez, who called this the “last piece in a perfect puzzle”. His post was shared by 4 HCPs, compared to Cristobal Morales who received 18 shares by his HCP peers.
Semaglutide superior to placebo in MASH resolution and fibrosis regression in F2-F3 patients at 72 weeks: a third improved fibrosis and two thirds NASH resolution in Essence study @NovoNordiskES @AEEHLiver @sapdes the last piece in a perfect puzzle @EASLnews @AASLDtweets 👏🔝👏 pic.twitter.com/R77WjWAtLc
— Manuel Romero-Gómez (@mromerogomez) November 1, 2024
On 04 December, DOL Daniel Drucker returned to the weight loss conversation by sharing the results of the SURMOUNT-5 trial which demonstrated higher efficacy of tirzepatide compared to semaglutide. He stated that in this race of weight loss treatments, “tirzepatide notches a win”.
Tirzepatide notches a win, demonstrating superiority vs. Semaglutide for #weightloss #obesity in SURMOUNT-5 @EliLillyandCo @novonordisk $LLY $NVO https://t.co/oxQp4K7dT5 pic.twitter.com/IJTbQDzl9M
— Daniel J Drucker (@DanielJDrucker) December 4, 2024
A few weeks later, Daniel Drucker jumped back into the weight loss conversation again on 20 December to share the press release from Novo Nordisk that reported on the results from the REDEFINE-1 trial, tagging Novo Nordisk in his post.
Cagri-Sema produces ~20% placebo subtracted weight loss in people with obesity studied in REDEFINE-1 @novonordisk https://t.co/HHk4vJ73gQ pic.twitter.com/rt6QBfPzyg
— Daniel J Drucker (@DanielJDrucker) December 20, 2024
Daniel Drucker’s was shared by 13 HCPs. The REDEFINE-1 trial also caught the attention of DOL Cristobal Morales who also shared the news. His post also resonated with HCP peers globally, with 11 HCPs sharing his post about the REDEFINE-1 trial – becoming the second most shared HCP post about the trial when mentioning a pharmaceutical company.
Other developments
On 06 October, the Options 2024 conference took place, where HCPs gathered to discuss the detection, treatment and control of influenza and other respiratory diseases. Physician Raina MacIntyre posted from the conference, calling it a “pleasure to talk about #influenza and #cardiovascular disease at the @sanofi symposium”.
Great @options2024 conference – and a pleasure to talk about #influenza and #cardiovascular disease at the @sanofi symposium. With Prof Bruno Lina, Prof LJTan Prof @TorBiering and Dr Meral Akcay pic.twitter.com/CL7hguF8h2
— Raina MacIntyre (@Globalbiosec) October 6, 2024
Between 16 and 18 November, the American Heart Association AHA) 2024 congress took place in Chicago, Illinois. At the congress HCPs gathered to discuss the latest developments in the field of cardiovascular diseases and cardiology, discussing treatment options, scientific developments and networking with peers. On 17 November, Professor Maciej Banach posted from the Amgen booth with his peers about a network of “#lipid #fighters”, calling it an “amazing initiative” from Amgen.
Amazing initiative at the @Amgen Booth at the #AHA2024 to present an international network of #lipid #fighters and finally listen to your #heart ‼️👏 @SABOURETCardio @cwojcik @DrNathanWong @American_Heart pic.twitter.com/6T7CdNVFvu
— Maciej Banach (@maciejbanach) November 17, 2024
On 22 November, cardiologist Annabelle Volgman thanked BMS, Gilead and Amgen for their work in programs to enhance clinical trial diversity. She stated that she was “so impressed” with the cohort and congratulated her peers for winning the “Robert A. Winn Excellence in Clinical Trials Awards”
So impressed w/ @WinnAwards Cohort 4 – recipients of funding for protected time to do their research projects! Thanks @DrRobWinn @VCUMassey @bmsnews @GileadSciences @AmgenFoundation Congrats @DhariniRamu @danseungkim pic.twitter.com/6druKy7hLK
— AnnabelleVolgman MD (@avolgman) November 22, 2024
Should pharmaceutical companies listen to online HCPs?
Over the last quarter, HCPs celebrated online when pharmaceutical companies reached endpoints to cancer treatment trials, supported initiatives to address the disparity in clinical trial diversity and worked on treatment options that provide more options to patients.
The top shared links by HCPs when mentioning a Top 50 pharma company discussed:
- A journal article about Novavax’s COVID-19 vaccine side effects compared to competitors.
- A link to Novo Nordisk’s press release site.
- A PDF download of a nephrology publication sponsored by AstraZeneca.
It’s clear that many HCPs rely on social media to discover and share new medical science. As well as being amplifiers and disseminators of new science, their collective and individual voices provide a powerful guide to how physicians think new treatments will shape patient care now and in the future.
By listening to the online voice of healthcare professionals, medicine manufacturers can discover what’s important to physicians on the front lines of patient care, find out whether their messaging about new medicines is resonating, and predict future HCP behaviours.
At CREATION.co, we’ve been tracking the online HCP voice for over a decade, thanks to our specialist technology platform, CREATION Pinpoint. Talk with us about how our insights can inspire your next innovation.
——
Find out how the conversation is changing in other Top 50 Trackers and new analysis of the online HCP conversation in a variety of topics.
You can also receive these updates and more straight to your inbox by signing up to CREATION.co’s monthly eJournal.
Methodology notes:
-
- In October – December 2024, CREATION Pinpoint® identified 23,806 posts on X (Twitter) from 7,224 individual HCPs mentioning a Top 50 Pharmaceutical company (based on revenue).
- Data for this research was analysed from the online X conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 September – 31 December 2024.
- Unless otherwise specified, mentions of a company are not limited to its X account(s).
- In some cases, a post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Johnson & Johnson Innovative Medicine (previously Janssen). In October – December 2024, 187 of these posts mentioned Johnson & Johnson Innovative Medicine or Janssen.